SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell-engaging bispecific antibodies as potential therapeutics in oncology.
News Ticker
- [ September 26, 2023 ] Muscle Lab Ignites a Wellness Evolution with the Launch of GPT-4 Driven Custom Recovery Plans and Smart Lab Los Angeles Biotech News
- [ September 26, 2023 ] Herbalife Steps Up to Support Healthy Active Lifestyles for 10th Consecutive Year as Nutrition Partner for Downtown Los Angeles YMCA’s Stair Climb & Urban Hike Los Angeles Biotech News
- [ September 26, 2023 ] CLININICAL LAB SCIENTIST I – PD – IRVINE HEMATOLOGY – Hoag Memorial Hospital Presbyterian – Irvine, CA Los Angeles Biotech Jobs
- [ September 26, 2023 ] How TikTok’s algorithm and audiences are finally convincing Big Pharma to join Los Angeles Biotech News
- [ September 26, 2023 ] Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
